UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 149

Sortiert nach

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

American journal of transplantation, 2013-06, Vol.13 (6), p.1601-1605

2013

Volltextzugriff (PDF)

LP27 : ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase

Journal of hepatology, 2015-04, Vol.62, p.S277-S277

2015

Volltextzugriff (PDF)

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

Journal of hepatology, 2013-04, Vol.58, p.S570-S570

2013

Volltextzugriff (PDF)

1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS

Journal of hepatology, 2012-04, Vol.56, p.S441-S441

2012

Volltextzugriff (PDF)

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Journal of hepatology, 2012-04, Vol.56, p.S560-S560

2012

Volltextzugriff (PDF)

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

Journal of hepatology, 2011-03, Vol.54, p.S544-S545

2011

Volltextzugriff (PDF)

1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL

Journal of hepatology, 2010, Vol.52, p.S462-S462

2010

Volltextzugriff (PDF)

[517] ETV RE-TREATMENT OF NUCLEOSIDE-NAIVE HBeAg(−) PATIENTS

Journal of hepatology, 2007, Vol.46, p.S197-S197

2007

Volltextzugriff (PDF)

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Gastroenterology (New York, N.Y. 1943), 2005-10, Vol.129 (4), p.1198-1209

2005

Volltextzugriff (PDF)

Agranulocytosis induced by abacavir

AIDS (London), 1999-07, Vol.13 (11), p.1420-1421

1999

Volltextzugriff (PDF)

Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin

Antimicrobial Agents and Chemotherapy, 1989-07, Vol.33 (7), p.1019-1022

1989

Volltextzugriff (PDF)

Aggression and war: Their biological and social bases

1989

Volltextzugriff (PDF)

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial

Critical care medicine, 1995-06, Vol.23 (6), p.994-1006

1995

Volltextzugriff (PDF)

43 Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study A1463-014

Journal of hepatology, 2004, Vol.40, p.16-16

2004

Volltextzugriff (PDF)

Ratchet-type marginal fracture of the radial head with locked anterior dislocation : a case report

Clinical orthopaedics and related research, 1991-04, Vol.265 (265), p.196-199

1991

Volltextzugriff (PDF)

Summary of phase II clinical and laboratory safety experience with Entecavir

Journal of hepatology, 2003-04, Vol.38, p.170-170

2003

Volltextzugriff (PDF)

Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results

Journal of clinical virology, 2006-01, Vol.36, p.S95-S95

2006

Volltextzugriff (PDF)

P.110 Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results

Journal of clinical virology, 2006, Vol.36, p.S95-S95

2006

Volltextzugriff (PDF)

512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B

Journal of hepatology, 2006-04, Vol.44, p.S190-S191

2006

Volltextzugriff (PDF)

PGI16 HEALTH RELATED QUALITY OF LIFE CHANGES IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB PATIENTS AFTER ENTECAVIR (ETV) OR LAMIVUDINE (LAM) TREATMENT¡V BMS STUDY 026

Value in health, 2005-05, Vol.8 (3), p.374-374

2005

Volltextzugriff (PDF)

O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Journal of clinical virology, 2006, Vol.36, p.S55-S55

2006

Volltextzugriff (PDF)

Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Journal of clinical virology, 2006-01, Vol.36, p.S55-S55

2006

Volltextzugriff (PDF)

428 Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy

Journal of hepatology, 2004, Vol.40, p.127-127

2004

Volltextzugriff (PDF)

442 Entecavir 10 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine-refractory patients

Journal of hepatology, 2004, Vol.40, p.131-131

2004

Volltextzugriff (PDF)

Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBEAG-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy

Journal of hepatology, 2003-04, Vol.38, p.32-33

2003

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(141)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(149)
Japanisch
(17)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

LP27 : ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL

[517] ETV RE-TREATMENT OF NUCLEOSIDE-NAIVE HBeAg(−) PATIENTS

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Agranulocytosis induced by abacavir

Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin

Aggression and war: Their biological and social bases

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial

43 Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study A1463-014

Ratchet-type marginal fracture of the radial head with locked anterior dislocation : a case report

Summary of phase II clinical and laboratory safety experience with Entecavir

Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results

P.110 Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results

512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B

PGI16 HEALTH RELATED QUALITY OF LIFE CHANGES IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB PATIENTS AFTER ENTECAVIR (ETV) OR LAMIVUDINE (LAM) TREATMENT¡V BMS STUDY 026

O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

428 Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy

442 Entecavir 10 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine-refractory patients

Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBEAG-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy

Suchergebnisse filtern